214 related articles for article (PubMed ID: 35147860)
1. Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
Sharma A; Sinha S; Rathaur P; Vora J; Jha PC; Johar K; Rawal RM; Shrivastava N
Mol Divers; 2022 Dec; 26(6):3337-3356. PubMed ID: 35147860
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
4. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
Zhou J; Ji Q; Li Q
J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
[TBL] [Abstract][Full Text] [Related]
5. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
6. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
[TBL] [Abstract][Full Text] [Related]
7. Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
Arowosegbe MA; Amusan OT; Adeola SA; Adu OB; Akinola IA; Ogungbe BF; Omotuyi OI; Saibu GM; Ogunleye AJ; Kanmodi RI; Lugbe NE; Ogunmola OJ; Ajayi DC; Ogun SO; Oyende FO; Bello AO; Ishola PG; Obasieke PE
Curr Drug Discov Technol; 2020; 17(5):682-695. PubMed ID: 31441728
[TBL] [Abstract][Full Text] [Related]
8. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.
Misale S; Bozic I; Tong J; Peraza-Penton A; Lallo A; Baldi F; Lin KH; Truini M; Trusolino L; Bertotti A; Di Nicolantonio F; Nowak MA; Zhang L; Wood KC; Bardelli A
Nat Commun; 2015 Sep; 6():8305. PubMed ID: 26392303
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
[TBL] [Abstract][Full Text] [Related]
10. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
12. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Mangiapane LR; Nicotra A; Turdo A; Gaggianesi M; Bianca P; Di Franco S; Sardina DS; Veschi V; Signore M; Beyes S; Fagnocchi L; Fiori ME; Bongiorno MR; Lo Iacono M; Pillitteri I; Ganduscio G; Gulotta G; Medema JP; Zippo A; Todaro M; De Maria R; Stassi G
Gut; 2022 Jan; 71(1):119-128. PubMed ID: 33436496
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
14. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
15. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
De Cuyper A; Van Den Eynde M; Machiels JP
Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
[TBL] [Abstract][Full Text] [Related]
16. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
18. An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
Majhi M; Ali MA; Limaye A; Sinha K; Bairagi P; Chouksey M; Shukla R; Kanwar N; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(27):2355-2366. PubMed ID: 30499396
[TBL] [Abstract][Full Text] [Related]
19. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
